

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HARBOUR
BIOMED
和 鉑 醫 藥 控 股 有 限 公 司
HBM Holdings Limited

(incorporated in the Cayman Islands with limited liability)
(Stock Code: 02142)

INSIDE INFORMATION
UPDATE ON COLLABORATION
WITH CULLINAN THERAPEUTICS, INC. FOR HBM7008

This announcement is made by HBM Holdings Limited (the “**Company**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

Reference is made to the announcement of the Company dated 14 February 2023 (the “**Announcement**”) in relation to the collaboration between Harbour BioMed US Inc. (“**Harbour**”) and Cullinan Therapeutics, Inc. (formerly known as Cullinan Oncology, Inc., “**Cullinan**”). Unless otherwise defined, capitalised terms used herein shall have the same meaning as defined in the Announcement.

As mentioned in the Announcement, pursuant to the Agreement, Cullinan is responsible for the development and commercialization of the Licensed Products in the Territory at its own costs. The Board hereby announces that the Company received a termination notice from Cullinan terminating the Agreement (the “**Termination**”) which will become effective on 3 November 2024, and Harbour shall be under no obligation to return any monies received under the Agreement prior to the Termination. Harbour will regain the global right of HBM7008 and will continue to explore other development and potential commercialization opportunities. Further announcement(s) will be made by the Company as and when appropriate.

Warning under Rule 18A.05 of the Listing Rules: There is no assurance that any products as stated in this announcement will ultimately be successfully developed and marketed by the Company. Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
HBM Holdings Limited
Dr. Jingsong Wang
Chairman and Executive Director

Hong Kong, 8 August 2024

As at the date of this announcement, the board of directors of the Company comprises Dr. Jingsong Wang and Dr. Yiping Rong as executive Directors; Ms. Weiwei Chen as non-executive Director; Dr. Robert Irwin Kamen, Dr. Xiaoping Ye and Dr. Albert R. Collinson as independent non-executive Directors.